Press

The union of synthetic biology, artificial intelligence, and automation drives new biofuels, proteins, and gene therapies

09/10/2025

BioSpain

• Artificial intelligence enables the analysis of millions of biological data points to identify optimal solutions, while automation facilitates the transfer of results from the lab to industry.
• Cultivated meat and plant-based proteins are revolutionizing the meat industry with nutrient-rich, safer foods: they reduce risks associated with zoonotic pathogens, antibiotic residues, and microbiological contaminants.
• Gas fermentation and the use of photosynthetic organisms make it possible to convert CO₂ into high-value bioproducts such as biofuels, bioplastics, proteins, and biomass for food or fertilizers.

AseBio

BIOSPAIN 2025 closes with record attendance and passes the baton to Bilbao as 2026 host city

09/10/2025

BioSpain

• The edition closes with more than 2,400 attendees from over 1,000 organizations across 34 countries.
• BIOSPAIN 2025 brought together 140 investors representing 76 national and international investment entities, and facilitated more than 4,500 meetings.
• BIOSPAIN consolidates itself as a strategic platform to strengthen public-private cooperation, boost the internationalization of biotech companies, and foster frontier research.
  
   

AseBio

Investing in Biotechnology: A Commitment to Excellence and the Real Impact of Innovation on Patients

08/10/2025

BioSpain

• Experts advocate for the convergence of biotechnology, engineering, and digitalization as a driving force for industrial transformation, while emphasizing the need for multidisciplinary talent and collaborative frameworks to accelerate innovation.
• The Spanish biotech ecosystem, despite its progress in investment, R&D, business creation, and international visibility, still needs to strengthen public-private collaborations and take greater advantage of European funding instruments.
• Venture capital funds are a key driver of growth for biotech start-ups, which must balance their high capital needs with the inherent uncertainty of the sector.
   

AseBio

Advanced therapies: a strategic pillar for European autonomy in biotechnology and health

08/10/2025

BioSpain

• Early Health Technology Assessment (HTA) prevents investments in developments that will not deliver real value, while allowing patients faster access to truly innovative treatments.
• The upcoming Biotech Act and the European Pharmaceutical Strategy are crucial for the development of advanced therapies in Europe, as they aim to create a more agile and predictable regulatory framework that facilitates innovation, clinical research, and industrial production of these treatments.
• Experts point out that effective implementation of artificial intelligence in hospital settings requires proper data infrastructure, interoperability strategies, and clear regulatory frameworks to accelerate clinical impact.
  
   

AseBio

From Vertical Sector to Critical Technology: Biotechnology at the Epicenter of the New Global Geopolitical Map

07/10/2025

BioSpain

• AseBio presents at BIOSPAIN 2025 the report “The new geopolitics of biotechnology”, which analyzes the global race of the sector and Spain’s strategic role in the new balance of power among the United States, Europe, and China.
• The United States leads biotechnology, but its hegemony is being challenged by China’s rapid rise in patents and research. Europe, positioned between the two, remains relevant but must narrow its innovation gap to remain competitive.
• The Spanish model has shown strength in R&D, but it must transform into commercial success, job creation, and economic leadership.

AseBio

BIOSPAIN 2025 kicks off in Barcelona: the leading national meeting point for biotechnology and one of Europe’s top references

07/10/2025

BioSpain

• From October 7–9, the Fira de Barcelona will host the 12th edition of BIOSPAIN, organized by AseBio and Biocat, in collaboration with the Government of Catalonia and the Barcelona City Council.
• The opening ceremony featured Rocío Arroyo, President of AseBio; Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities; Antoni Plasència i Taradach, Director General for Research and Innovation at the Department of Health of the Government of Catalonia; and Jordi Valls Riera, Deputy Mayor for Economy, Housing, Treasury and Tourism of the Barcelona City Council.
• One of this year’s major novelties: BIOSPAIN will now become an annual event instead of a biennial one. The host city for BIOSPAIN 2026 will be announced on October 9 in a special ceremony.
   

AseBio

Personalized Vaccines, CAR-T, and AI: The New Horizon of Cancer Research

24/09/2025

Healthcare · Innovative drugs · Personalized medicine · Advanced therapies

• Cancer research is advancing thanks to biotechnology, but it still faces challenges such as equitable access and the need for stable funding.
• On World Cancer Research Day, the AECC Scientific Foundation reminds us that only through the joint commitment of patients, healthcare professionals, and the research community will it be possible to achieve more significant breakthroughs and improve quality of life.
• Sofía Cabezudo, Head of Innovation, highlights the role of biotechnology in driving innovative therapies, enhancing treatment personalization, and placing the patient at the center of cancer research.

AseBio

Sepsis causes up to 20,000 annual deaths in Spain: Biotechnology is revolutionizing early diagnosis

13/09/2025

Healthcare · Personalized medicine

• At a global scale, according to WHO data, between 48 and 50 million cases are estimated each year, with at least 11 million deaths.
• Early detection and biotechnological innovation — ultrafast diagnosis, personalized medicine, and comprehensive support — are key to saving lives and reducing long-term effects.
• Viva In Vitro, an AseBio member, has developed VIVA-ELISA, a biotechnology tool that rapidly detects activation of the NLRP3 inflammasome, enabling evaluation of the immune system’s ability to respond even before clinical symptoms appear.
   

AseBio

BIOSPAIN becomes an annual event, consolidating its leadership as a driving force of the Spanish biotechnology sector

09/09/2025

BioSpain

• BIOSPAIN 2025 will take place from October 7 to 9 in Barcelona, under the motto 'Global crossroads, local vibes', with the aim of connecting local talent with European and American ecosystems.
• The eleventh edition in 2023 achieved record participation figures, bringing together more than 2,200 attendees from nearly 1,000 companies across 34 countries, and generating over 5,000 one-to-one meetings. Expectations are that this edition will reach an equal or greater impact.
• The host city for BIOSPAIN 2026 will be announced during the official events at BIOSPAIN 2025, while Barcelona is confirmed as the venue for the 2027 and 2029 editions.
   

AseBio